<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39276195</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-069X</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Archives of dermatological research</Title><ISOAbbreviation>Arch Dermatol Res</ISOAbbreviation></Journal><ArticleTitle>The role of IL-17 and Th17 cells in keloid pathogenesis.</ArticleTitle><Pagination><StartPage>626</StartPage><MedlinePgn>626</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00403-024-03352-y</ELocationID><Abstract><AbstractText>Keloids are characterized histologically by excessive fibroblast proliferation and connective tissue deposition, and clinically by scar tissue extending beyond the original site of skin injury. These scars can cause pruritus, pain, physical disfigurement, anxiety, and depression. As a result, keloid patients often have a diminished quality of life with a disproportionate burden on ethnic minorities. Despite advances in understanding keloid pathology, there is no effective Food and Drug Administration (FDA)-approved pharmacotherapy. Recent studies have highlighted the possible pathologic role of T helper (Th)17 cells and interleukin (IL)-17 in keloid formation, as well as their implication in other inflammatory disorders. This systematic review characterizes the role of Th17 cells and IL-17 in keloid pathogenesis, highlighting this pathway as a potential therapeutic target. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive search on PubMed, Embase, MEDLINE, and Web of Science databases on June 5, 2024. The search included terms related to Th17 cells, IL-17, and keloids. Thirteen studies met the inclusion criteria, comprising basic science and bioinformatic studies focusing on Th17 cells and IL-17. Key findings include increased Th17 cell infiltration and IL-17 expression in keloids, IL-17's role in amplifying the inflammatory and fibrotic response via the promotion of IL-6 expression, and IL-17's involvement in upregulating fibrotic markers via SDF-1 and HIF-1α pathways. IL-17 also activates the transforming growth factor beta (TGF-β)/Smad pathway in keloid fibroblasts. Th17 cells and IL-17 significantly contribute to the inflammatory and fibrotic processes in keloid pathogenesis. Therefore, targeting the IL-17 pathway offers a potential new therapeutic target to improve keloid patients' outcomes. Future research could further elucidate the role of Th17 cells and IL-17 in keloid pathogenesis and assess the safety and efficacy of targeting this pathway in human studies.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bitterman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York Medical College, Valhalla, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zafar</LastName><ForeName>Kayla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. George's University School of Medicine, Grenada, West Indies, True Blue, Grenada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabakova</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Paras</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joerg</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Albany Medical College, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagdeo</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, USA. jrjagdeo@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA. jrjagdeo@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arch Dermatol Res</MedlineTA><NlmUniqueID>8000462</NlmUniqueID><ISSNLinking>0340-3696</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="Y">Interleukin-17</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007627" MajorTopicYN="Y">Keloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="Y">Th17 Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">IL-17</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Keloid</Keyword><Keyword MajorTopicYN="N">Pathogenesis</Keyword><Keyword MajorTopicYN="N">Th17</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>14</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39276195</ArticleId><ArticleId IdType="doi">10.1007/s00403-024-03352-y</ArticleId><ArticleId IdType="pii">10.1007/s00403-024-03352-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mony MP et al (2023) Updated Rev Hypertrophic Scarring Cells, 12(5)</Citation></Reference><Reference><Citation>Limandjaja GC et al (2021) Hypertrophic scars and keloids: overview of the evidence and practical guide for differentiating between these abnormal scars. Exp Dermatol 30(1):146–161</Citation><ArticleIdList><ArticleId IdType="pubmed">32479693</ArticleId><ArticleId IdType="doi">10.1111/exd.14121</ArticleId></ArticleIdList></Reference><Reference><Citation>Betarbet U, Blalock TW (2020) Keloids: a review of etiology, Prevention, and treatment. J Clin Aesthet Dermatol 13(2):33–43</Citation><ArticleIdList><ArticleId IdType="pubmed">32308783</ArticleId><ArticleId IdType="pmc">7158916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijlard E et al (2017) Burden of Keloid Disease: a cross-sectional health-related quality of Life Assessment. Acta Derm Venereol 97(2):225–229</Citation><ArticleIdList><ArticleId IdType="pubmed">27378582</ArticleId><ArticleId IdType="doi">10.2340/00015555-2498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Chu H, Zheng X (2021) Effects on quality of life and psychosocial wellbeing in Chinese patients with keloids. Am J Transl Res 13(3):1636–1642</Citation><ArticleIdList><ArticleId IdType="pubmed">33841685</ArticleId><ArticleId IdType="pmc">8014351</ArticleId></ArticleIdList></Reference><Reference><Citation>Olopoenia A et al (2024) Demographics, clinical characteristics, and treatment patterns among keloid patients: United States Electronic Health Records (EHR) Database Study. Int J Dermatol</Citation></Reference><Reference><Citation>Sarah McGinty WJS, Keloid (2023) [Internet] [cited September 20, 2023; https://www.ncbi.nlm.nih.gov/books/NBK507899/</Citation></Reference><Reference><Citation>Insights FM (2023) Keloid Treatment Market Outlook (2023 to 2033). [cited June 26, 2024</Citation></Reference><Reference><Citation>Wang ZC et al (2020) The roles of inflammation in Keloid and hypertrophic scars. Front Immunol 11:603187</Citation><ArticleIdList><ArticleId IdType="pubmed">33343575</ArticleId><ArticleId IdType="pmc">7746641</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.603187</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CC et al (2023) An updated review of the immunological mechanisms of keloid scars. Front Immunol 14:1117630</Citation><ArticleIdList><ArticleId IdType="pubmed">37033989</ArticleId><ArticleId IdType="pmc">10075205</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1117630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong YK et al (2023) Inflammation in Wound Healing and pathological scarring. Adv Wound Care (New Rochelle) 12(5):288–300</Citation><ArticleIdList><ArticleId IdType="pubmed">36541356</ArticleId><ArticleId IdType="doi">10.1089/wound.2021.0161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazizadeh M (2007) Essential role of IL-6 signaling pathway in keloid pathogenesis. J Nippon Med Sch 74(1):11–22</Citation><ArticleIdList><ArticleId IdType="pubmed">17384473</ArticleId><ArticleId IdType="doi">10.1272/jnms.74.11</ArticleId></ArticleIdList></Reference><Reference><Citation>Do DV et al (2012) Interleukin-18 system plays an important role in keloid pathogenesis via epithelial–mesenchymal interactions. Br J Dermatol 166(6):1275–1288</Citation><ArticleIdList><ArticleId IdType="pubmed">22050194</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2133.2011.10721.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Li B, Zhao M (2021) Therapeutic strategies by regulating Interleukin Family to suppress inflammation in hypertrophic scar and keloid. Front Pharmacol 12:667763</Citation><ArticleIdList><ArticleId IdType="pubmed">33959031</ArticleId><ArticleId IdType="pmc">8093926</ArticleId><ArticleId IdType="doi">10.3389/fphar.2021.667763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AR et al (2023) Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: patient-derived keloid xenograft (PDKX) model. Exp Mol Med 55(8):1713–1719</Citation><ArticleIdList><ArticleId IdType="pubmed">37524866</ArticleId><ArticleId IdType="pmc">10474158</ArticleId><ArticleId IdType="doi">10.1038/s12276-023-01045-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XY, Wu XF, Li DQ (2023) The communication from Immune cells to the fibroblasts in Keloids: implications for Immunotherapy. Int J Mol Sci, 24(20)</Citation></Reference><Reference><Citation>Tang Y et al (2023) Tissue RNA sequencing reveals novel biomarkers Associated with Postoperative Keloid recurrence. J Clin Med, 12(17)</Citation></Reference><Reference><Citation>Yan Q, Li B (2022) TRAF3IP2 regulated by FOXO4 affects fibroblast proliferation, migration, and extracellular matrix deposition in keloid through the TGF-β1/Smad pathway. J Cosmet Dermatol 21(10):5148–5155</Citation><ArticleIdList><ArticleId IdType="pubmed">35441794</ArticleId><ArticleId IdType="doi">10.1111/jocd.15009</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y et al (2012) IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ/Erk1/2/NF-κB-dependent signaling pathway. Int Immunol 24(10):605–612</Citation><ArticleIdList><ArticleId IdType="pubmed">22531062</ArticleId><ArticleId IdType="doi">10.1093/intimm/dxs056</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang D et al (2023) Interleukin-17A plays a key role in pulmonary fibrosis following Propionibacterium acnes-induced sarcoidosis-like inflammation. Exp Biol Med (Maywood) 248(14):1181–1190</Citation><ArticleIdList><ArticleId IdType="pubmed">37452708</ArticleId><ArticleId IdType="doi">10.1177/15353702231182224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie YJ et al (2022) Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis. Mil Med Res 9(1):21</Citation><ArticleIdList><ArticleId IdType="pubmed">35550651</ArticleId><ArticleId IdType="pmc">9102601</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F et al (2012) Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143(3):765–776e3</Citation><ArticleIdList><ArticleId IdType="pubmed">22687286</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2012.05.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisto M, Lisi S (2023) Targeting Interleukin-17 as a Novel Treatment option for Fibrotic diseases. J Clin Med, 13(1)</Citation></Reference><Reference><Citation>Weng CH et al (2020) Interleukin-17A induces renal fibrosis through the ERK and Smad signaling pathways. Biomed Pharmacother 123:109741</Citation><ArticleIdList><ArticleId IdType="pubmed">31901549</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2019.109741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstein SF et al (2021) Keloids: a review of therapeutic management. Int J Dermatol 60(6):661–671</Citation><ArticleIdList><ArticleId IdType="pubmed">32905614</ArticleId><ArticleId IdType="doi">10.1111/ijd.15159</ArticleId></ArticleIdList></Reference><Reference><Citation>El Kinani M, Duteille F et al (2020) Scar Epidemiology and Consequences, in Textbook on Scar Management: State of the Art Management and Emerging Technologies, L. Téot, Editors. Springer Copyright 2020, The Author(s). Cham (CH). pp. 45 – 9</Citation></Reference><Reference><Citation>Al Zahrani RA et al (2023) Comprehensive Analysis of Current Treatment approaches for keloids in Pediatrics: a systematic review. Cureus 15(12):e50290</Citation><ArticleIdList><ArticleId IdType="pubmed">38205454</ArticleId><ArticleId IdType="pmc">10776453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauglitz GG (2013) Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol 6:103–114</Citation><ArticleIdList><ArticleId IdType="pubmed">23637546</ArticleId><ArticleId IdType="pmc">3639020</ArticleId><ArticleId IdType="doi">10.2147/CCID.S35252</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y et al (2021) The polygenic map of keloid fibroblasts reveals Fibrosis-Associated gene alterations in inflammation and Immune responses. Front Immunol 12:810290</Citation><ArticleIdList><ArticleId IdType="pubmed">35082796</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.810290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B et al (2024) Identification and validation of CCR5 linking keloid with atopic dermatitis through comprehensive bioinformatics analysis and machine learning. Front Immunol 15:1309992</Citation><ArticleIdList><ArticleId IdType="pubmed">38476235</ArticleId><ArticleId IdType="pmc">10927814</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1309992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Lin G, Wang Z (2021) Bioinformatics study on different gene expression profiles of fibroblasts and vascular endothelial cells in keloids. Med (Baltim) 100(47):e27777</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000027777</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J et al (2020) RNA sequencing keloid Transcriptome associates Keloids with Th2, Th1, Th17/Th22, and JAK3-Skewing. Front Immunol 11:597741</Citation><ArticleIdList><ArticleId IdType="pubmed">33329590</ArticleId><ArticleId IdType="pmc">7719808</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.597741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B et al (2024) Identification and validation of CCR5 linking keloid with atopic dermatitis through comprehensive bioinformatics analysis and machine learning. Front Immunol 15:14</Citation></Reference><Reference><Citation>Zhang Q et al (2009) Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS ONE 4(11):e7798</Citation><ArticleIdList><ArticleId IdType="pubmed">19907660</ArticleId><ArticleId IdType="pmc">2771422</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0007798</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita M et al (2019) NEDD4 is involved in inflammation development during keloid formation. J Invest Dermatol 139(2):333–341</Citation><ArticleIdList><ArticleId IdType="pubmed">30273597</ArticleId><ArticleId IdType="doi">10.1016/j.jid.2018.07.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G, Jin Y (2010) Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther 1(5):39</Citation><ArticleIdList><ArticleId IdType="pubmed">21156086</ArticleId><ArticleId IdType="pmc">3025441</ArticleId><ArticleId IdType="doi">10.1186/scrt39</ArticleId></ArticleIdList></Reference><Reference><Citation>Granick M et al (2011) Telomere dynamics in keloids. Eplasty 11:e15</Citation><ArticleIdList><ArticleId IdType="pubmed">21436892</ArticleId><ArticleId IdType="pmc">3060056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KW et al (2007) Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 56(4):1076–1086</Citation><ArticleIdList><ArticleId IdType="pubmed">17393416</ArticleId><ArticleId IdType="doi">10.1002/art.22439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY et al (2020) IL-17 Induced Stromal Cell-Derived Factor-1 and profibrotic factor in keloid-derived skin fibroblasts &lt; i &gt; via the STAT3 pathway. Inflammation 43(2):664–672</Citation><ArticleIdList><ArticleId IdType="pubmed">31814061</ArticleId><ArticleId IdType="doi">10.1007/s10753-019-01148-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli L, Roth KA (2010) Autophagy Am J Pathol 176(3):1065–1071</Citation><ArticleIdList><ArticleId IdType="pubmed">20150434</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2010.090850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY et al (2022) IL-17 induces Autophagy Dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts &lt; i &gt; via the STAT3 and HIF-1a Dependent Signaling pathways. Front Immunol 13:9</Citation></Reference><Reference><Citation>Li S et al (2022) Relative perfusion index: an objective, quantitative and noninvasive method for evaluating the severity of keloids. Lasers Surg Med 54(8):1071–1081</Citation><ArticleIdList><ArticleId IdType="pubmed">35822861</ArticleId><ArticleId IdType="doi">10.1002/lsm.23579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY et al (2022) IL-17 induces Autophagy Dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts via the STAT3 and HIF-1α Dependent Signaling pathways. Front Immunol 13:888719</Citation><ArticleIdList><ArticleId IdType="pubmed">35757697</ArticleId><ArticleId IdType="pmc">9226909</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.888719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemer G et al (2020) A novel TRAF3IP2 variant causing familial scarring alopecia with mixed features of discoid lupus erythematosus and folliculitis decalvans. Clin Genet 98(2):116–125</Citation><ArticleIdList><ArticleId IdType="pubmed">32350852</ArticleId><ArticleId IdType="doi">10.1111/cge.13767</ArticleId></ArticleIdList></Reference><Reference><Citation>Das NA et al (2018) TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart. J Mol Cell Cardiol 121:107–123</Citation><ArticleIdList><ArticleId IdType="pubmed">29981796</ArticleId><ArticleId IdType="pmc">6732793</ArticleId><ArticleId IdType="doi">10.1016/j.yjmcc.2018.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinks TSC et al (2019) Activation and in vivo evolution of the MAIT Cell Transcriptome in mice and humans reveals tissue repair functionality. Cell Rep 28(12):3249–3262e5</Citation><ArticleIdList><ArticleId IdType="pubmed">31533045</ArticleId><ArticleId IdType="pmc">6859474</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.07.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurzat Y et al (2023) Invariant chain of the MAIT-TCR vα7.2-Jα33 as a novel diagnostic biomarker for keloids. Exp Dermatol 32(2):186–197</Citation><ArticleIdList><ArticleId IdType="pubmed">36309840</ArticleId><ArticleId IdType="doi">10.1111/exd.14700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY et al (2020) IL-17 Induced Stromal cell–derived Factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway. Inflammation 43(2):664–672</Citation><ArticleIdList><ArticleId IdType="pubmed">31814061</ArticleId><ArticleId IdType="doi">10.1007/s10753-019-01148-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki E et al (2014) The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 13(4–5):496–502</Citation><ArticleIdList><ArticleId IdType="pubmed">24424175</ArticleId><ArticleId IdType="pmc">3995976</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2014.01.050</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamuri S et al (2016) TRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE(-/-) mice. Atherosclerosis 252:153–160</Citation><ArticleIdList><ArticleId IdType="pubmed">27237075</ArticleId><ArticleId IdType="doi">10.1016/j.atherosclerosis.2016.05.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Alt EU et al (2018) TRAF3IP2, a novel therapeutic target in glioblastoma multiforme. Oncotarget 9(51):29772–29788</Citation><ArticleIdList><ArticleId IdType="pubmed">30038719</ArticleId><ArticleId IdType="pmc">6049871</ArticleId><ArticleId IdType="doi">10.18632/oncotarget.25710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu HH et al (2018) New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact 292:76–83</Citation><ArticleIdList><ArticleId IdType="pubmed">30017632</ArticleId><ArticleId IdType="doi">10.1016/j.cbi.2018.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger JG et al (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol 15:1331217</Citation><ArticleIdList><ArticleId IdType="pubmed">38686385</ArticleId><ArticleId IdType="pmc">11056518</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1331217</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooney LA et al (2011) Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J Immunol 187(9):4440–4450</Citation><ArticleIdList><ArticleId IdType="pubmed">21949021</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1002860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y et al (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133–145</Citation><ArticleIdList><ArticleId IdType="pubmed">34987201</ArticleId><ArticleId IdType="pmc">8730299</ArticleId><ArticleId IdType="doi">10.1038/s41584-021-00726-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Catlett IM et al (2023) First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci 16(1):151–164</Citation><ArticleIdList><ArticleId IdType="pubmed">36325947</ArticleId><ArticleId IdType="doi">10.1111/cts.13435</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai R et al (2024) Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open, 10(2)</Citation></Reference><Reference><Citation>Opdam MAA et al (2024) Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clin Rheumatol 43(6):2133–2138</Citation><ArticleIdList><ArticleId IdType="pubmed">38703283</ArticleId><ArticleId IdType="doi">10.1007/s10067-024-06980-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk K, Fakhoury J, Ozog D (2022) Nonresponse and progression of diffuse keloids to Dupilumab Therapy. J Drugs Dermatol 21(2):197–199</Citation><ArticleIdList><ArticleId IdType="pubmed">35133105</ArticleId><ArticleId IdType="doi">10.36849/JDD.6252</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirgan MH, Uitto J (2022) Lack of efficacy of dupilumab in the treatment of keloid disorder. J Eur Acad Dermatol Venereol 36(2):e120–e122</Citation><ArticleIdList><ArticleId IdType="pubmed">34537977</ArticleId><ArticleId IdType="doi">10.1111/jdv.17669</ArticleId></ArticleIdList></Reference><Reference><Citation>Min MS et al (2023) Successful treatment of keloids and hypertrophic scars with systemic and Intralesional Dupilumab. J Drugs Dermatol 22(12):1220–1222</Citation><ArticleIdList><ArticleId IdType="pubmed">38051859</ArticleId><ArticleId IdType="doi">10.36849/JDD.6385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmer A, Finklea L, Joseph J (2023) Effects of dupilumab on keloid stabilization and prevention. JAAD Case Rep 37:103–105</Citation><ArticleIdList><ArticleId IdType="pubmed">37360650</ArticleId><ArticleId IdType="pmc">10285468</ArticleId><ArticleId IdType="doi">10.1016/j.jdcr.2023.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AJS, Song EJ (2021) Dupilumab as an adjuvant treatment for keloid-associated symptoms. JAAD Case Rep 13:73–74</Citation><ArticleIdList><ArticleId IdType="pubmed">34179322</ArticleId><ArticleId IdType="pmc">8213974</ArticleId><ArticleId IdType="doi">10.1016/j.jdcr.2021.04.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz A et al (2020) Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. J Eur Acad Dermatol Venereol 34(4):e161–e164</Citation><ArticleIdList><ArticleId IdType="pubmed">31747457</ArticleId><ArticleId IdType="doi">10.1111/jdv.16097</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. NCT04988022: Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Keloid (2024) 2024/06/26] ; https://clinicaltrials.gov/study/NCT04988022?cond=Keloid%20dupilumab&amp;rank=1</Citation></Reference><Reference><Citation>Chen JY et al (2023) An Open-Label, uncontrolled, single-arm clinical trial of Tofacitinib, an oral JAK1 and JAK3 kinase inhibitor, in Chinese patients with Keloid. Dermatology 239(5):818–827</Citation><ArticleIdList><ArticleId IdType="pubmed">37643592</ArticleId><ArticleId IdType="doi">10.1159/000532064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa R (2022) The most current algorithms for the Treatment and Prevention of Hypertrophic Scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg 149(1):79e–94e</Citation><ArticleIdList><ArticleId IdType="pubmed">34813576</ArticleId><ArticleId IdType="doi">10.1097/PRS.0000000000008667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa R et al (2019) Surgical excision and postoperative radiotherapy for keloids. Scars Burn Heal 5:2059513119891113</Citation><ArticleIdList><ArticleId IdType="pubmed">31840001</ArticleId><ArticleId IdType="pmc">6904783</ArticleId></ArticleIdList></Reference><Reference><Citation>Chike-Obi CJ, Cole PD, Brissett AE (2009) Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 23(3):178–184</Citation><ArticleIdList><ArticleId IdType="pubmed">20676312</ArticleId><ArticleId IdType="pmc">2884925</ArticleId><ArticleId IdType="doi">10.1055/s-0029-1224797</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs.com. Cosentyx: History (2024) /06/26] ; https://www.drugs.com/history/cosentyx.html</Citation></Reference><Reference><Citation>Drugs.com. Taltz: History (2024) /06/26] ; https://www.drugs.com/history/taltz.html</Citation></Reference><Reference><Citation>Drugs.com. Bimzelx: History (2024) /06/26] ; https://www.drugs.com/history/bimzelx.html</Citation></Reference><Reference><Citation>Drugs.com. Siliq: History (2024) /06/26] ; https://www.drugs.com/history/siliq.html</Citation></Reference><Reference><Citation>Drugs.com. Stelara: History (2024) /06/26] ; https://www.drugs.com/history/stelara.html</Citation></Reference><Reference><Citation>Drugs.com. Tremfya: History (2024) /06/26] ; https://www.drugs.com/history/tremfya.html</Citation></Reference><Reference><Citation>Drugs.com. Ilumya: History (2024) /06/26] ; https://www.drugs.com/history/ilumya.html</Citation></Reference><Reference><Citation>Drugs.com. Skyrizi: History (2024) /06/26] ; https://www.drugs.com/history/skyrizi.html</Citation></Reference><Reference><Citation>Drugs.com. Actemra: History (2024) /06/27] ; https://www.drugs.com/history/actemra.html</Citation></Reference><Reference><Citation>Drugs.com. Kevzara: History (2024) /06/27] ; https://www.drugs.com/history/kevzara.html</Citation></Reference><Reference><Citation>Drugs.com. Enspryng: History (2024) /06/27] ; https://www.drugs.com/history/enspryng.html</Citation></Reference><Reference><Citation>Drugs.com. Sylvant: History (2024) /06/27] ; https://www.drugs.com/history/sylvant.html</Citation></Reference><Reference><Citation>Drugs.com. Xeljanz: History (2024) /06/27] ; https://www.drugs.com/history/xeljanz.html</Citation></Reference><Reference><Citation>Drugs.com. Olumiant: History (2024) /06/27] ; https://www.drugs.com/history/olumiant.html</Citation></Reference><Reference><Citation>Drugs.com. Jakafi: History (2024) /06/27] ; https://www.drugs.com/history/jakafi.html</Citation></Reference><Reference><Citation>Drugs.com. Opzelura: History (2024) /06/27] ; https://www.drugs.com/history/opzelura.html</Citation></Reference><Reference><Citation>Drugs.com. Leqselvi: History (2024) /08/04] ; https://www.drugs.com/history/leqselvi.html</Citation></Reference><Reference><Citation>Drugs.com. Rinvoq: History (2024) /06/27] ; https://www.drugs.com/history/rinvoq.html</Citation></Reference><Reference><Citation>Drugs.com. Cibinqo: History (2024) /06/27] ; https://www.drugs.com/history/cibinqo.html</Citation></Reference><Reference><Citation>Drugs.com. Sotyktu: History (2024) /06/27] ; https://www.drugs.com/history/sotyktu.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>